Crossmark

Efficacy comparison of 7- and 14-day P-CAB based bismuth-containing quadruple regimen with PPI based bismuth-containing quadruple regimen for Helicobacter pylori infection: rationale and design of an open-label, multicenter, randomized controlled trial

Crossref DOI link: https://doi.org/10.1186/s12876-023-03100-y

Published Online: 2023-12-21

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Oh, Chang Kyo

Lim, Hyun

Seo, Seung In

Lee, Sang Pyo

Bang, Chang Seok

Shin, Woon Geon

Kim, Jin Bae

Jang, Hyun Joo

Baik, Gwang Ho
Funding

Funding for this research was provided by:

HK inno.N
License Information

Text and Data Mining valid from 2023-12-21

Version of Record valid from 2023-12-21
More Information

Article History

Received: 19 April 2023

Accepted: 14 December 2023

First Online: 21 December 2023

Declarations

:

: This protocol had received approval from the MFDS in Korea and the IRB for human research at Hallym University-affiliated Hospital (No. 2021-09-013) before the study was initiated. The study protocol adheres to the CONSORT guidelines and Declaration of Helsinki as reflected in a priori endorsement by the institution’s human research committee. Written informed consent will be obtained before endoscopic examination.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below